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Abstract
Background: A number of studies, notably EPIC, have shown a descrease in colorectal cancer risk
associated with increased fibre consumption. Whilst the underlying mechanisms are likely to be
multifactorial, production of the short-chain fatty-acid butyrate fro butyratye is frequently cited as
a major potential contributor to the effect. Butyrate inhibits histone deacetylases, which work on
a wide range of proteins over and above histones. We therefore hypothesized that alterations in
the acetylated proteome may be associated with a cancer risk phenotype in the colorectal mucosa,
and that such alterations are candidate biomarkers for effectiveness of fibre interventions in cancer
prevention.
Methods an design: There are two principal arms to this study: (i) a cross-sectional study (FACT
OBS) of 90 subjects recruited from gastroenterology clinics and; (ii) an intervention trial in 40
subjects with an 8 week high fibre intervention. In both studies the principal goal is to investigate a
link between fibre intake, SCFA production and global protein acetylation. The primary measure is
level of faecal butyrate, which it is hoped will be elevated by moving subjects to a high fibre diet.
Fibre intakes will be estimated in the cross-sectional group using the EPIC Food Frequency
Questionnaire. Subsidiary measures of the effect of butyrate on colon mucosal function and pre-
cancerous phenotype will include measures of apoptosis, apoptotic regulators cell cycle and cell
division.
Discussion: This study will provide a new level of mechanistic data on alterations in the functional
proteome in response to the colon microenvironment which may underwrite the observed cancer
preventive effect of fibre. The study may yield novel candidate biomarkers of fibre fermentation and
colon mucosal function.
Trial Registration: Trial Registration Number: ISRCTN90852168
Published: 18 September 2009
BMC Cancer 2009, 9:332 doi:10.1186/1471-2407-9-332
Received: 6 August 2009
Accepted: 18 September 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/332
© 2009 Corfe et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 6
(page number not for citation purposes)
BMC Cancer 2009, 9:332 http://www.biomedcentral.com/1471-2407/9/332Background
Since Burkitt's original observations on the inverse corre-
lation between fibre (non-starch polysaccharides and
resistant starch) intake and prevalence of colorectal cancer
[1], a wide range of studies have addressed this relation-
ship and the possible mechanisms by which fibre may
protect against bowel cancer. Recent meta-analyses find a
strong evidence base to support consumption of fibre-
containing foods for prevention of several cancers [2], and
the majority of studies in this area are supportive. There
are exceptions, however, and two RCT studies, published
in 2000, failed to demonstrate a protective effect [3,4].
These controversial findings have been the subject of sev-
eral commentaries [5,6]. Potential explanations for this
conflicting data include: differences between US and EU
assays for fibre, different baseline levels of intake and the
limitations of adenoma recurrence as a model for primary
colorectal cancer prevention.
There are several mechanisms proposed for fibre's pro-
posed cancer-preventive properties. These include dilu-
tion of luminal contents; reduction in transit time, which
together will reduce exposure of the mucosa to luminal
toxin; adsorbtion of bile acids; and production of protec-
tive short chain fatty acids (SCFAs: principally acetate,
propionate and butyrate) through fermentation of fibre
by endosymbiotic bacteria. Studies in rats treated with a
colorectal carcinogen, have demonstrated a variable pro-
tective effect of different dietary fibre substrates and have
linked this with changes in the luminal SCFA profile [7].
Gibson et al for example found that when rats consumed
a diet with cellulose, a non-fermentable fibre, as principle
fibre source, little protection from DMH-induced carcino-
genesis was afforded. Oat-derived fibre, an acutely fer-
mentable fibre which is rapidly turned over to SCFA in the
caecum, but yields lower levels of SCFA in the distal colon
and rectum, provided improved protection, but maximal
protection was conferred by the more weakly fermentable
wheat fibre, which yielded higher levels of SCFA in the
distal colon and rectum. The study analysed SCFA levels
in rats' stools on each regimen and found that the strong-
est correlation with cancer prevention in this model
occurred on diets which gave maximal elevation of faecal
butyrate. Not surprisingly this data has led to a resurgence
of interest in the actions of butyrate.
Roediger [8] was first to show that butyrate is the preferred
metabolite of colon epithelial cells. In his studies, primary
epithelial cells from rat colon were incubated with
labelled glucose and labelled butyrate. Butyrate was found
to be metabolised in preference to glucose, which is avail-
able to colonocyte in vivo through the vasculature. The
use of butyrate as an energy souce is inefficient (by com-
parison with glucose) and it has been suggested that this
represents an evolutionary adaptation to recover the max-
imum energy available from the high-fibre diets con-
sumed by our paleolithic ancestors.
The effect of butyrate on cells grown in vitro is to drive
both cell cycle arrest and apoptosis. Both of these altera-
tions in cell fate occur at concentrations of butyrate read-
ily achieved in the colon lumen through fibre
fermentation. Cell cycle arrest has variously been reported
as G1 arrest, G2 arrest and mitotic bypass [9-11]. Several
reports have shown that the apoptosis triggered by
butyrate in vitro is associated with dysregulation of Bcl2
family proteins especially upregulation of BAK and down-
regulation of BclxL [12-14], rather than cellular damage.
These in vitro data contrast with studies on the in vivo or
ex vivo effects of butyrate. Takayama's studies investigat-
ing the effect of increasing fibre intake after restriction,
using a variety of animal models, have shown that switch-
ing to a high fibre diet is associated with an increase in
colon crypt length, cellularity and proliferation [15-17].
Hass [18] used ex vivo guinea pig colon mucosa in an Uss-
ing chamber model and monitored rates of cell death.
When tissue was maintained in an osmotically balanced
chamber, widespread cell death was found on the epithe-
lium and this was associated with up-regulation of Bax.
When butyrate was added to the chamber, however, there
was reduced cell death and no Bax upregulation. Further-
more, studies of diversion colitis show that widespread
cell death occurs after diversion of the faecal stream and
loss of luminal content [19]. This condition may be amel-
iorated by butyrate enema [20].
Recent studies have shown that elevation of luminal SCFA
causes no direct increase in levels of epithelial apoptosis
[21,22], but causes a significant increase in the level of
apoptosis after a genotoxic challenge. These in vivo data
are suggestive of a model whereby butyrate's antineoplas-
tic action is not in the induction of apoptosis per se, but
through sensitization of cells to damage. The observations
made in vitro that butyrate elevated levels of pro-apop-
totic Bcl2 family proteins, and downregulated their anti-
apoptotic counterparts could be predicted to sensitize
cells in precisely this way and we have recently proposed
this as a model [15].
How might butyrate alter cell functionality in this way?
Although recognised as a metabolite, butyrate is also a
potent inhibitor of histone deacetylases (HDACs) - [23].
HDACs are primarily recognised as one part of the regula-
tory mechanism for governing histone acetylation levels
in concert with their agonist enzymes the histone acetyl
transferases (HATs). The acetylation state of histones is
thought to be a potent governor of gene transcription at
both a specific and regional level of the chromatin. A
number of publications have shown widespread altera-Page 2 of 6
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with butyrate, indicating as much as 10% of genes may be
affected by butyrate either directly or indirectly. However
more recently several groups have identified other acetyl
proteins in the nucleus and cytosol, and HDAC activities
have been found in both cellular compartments [24,25].
Amongst the acetyl proteins identified are nuclear struc-
tural proteins, transcription factors including p53, Sp1,
Sp3 [26] and structural proteins including tubulin and
cytokeratins [27,28]. Our own preliminary findings using
pan-specific antiacetyl lysine antibodies indicate tens or
hundreds of acetyl proteins in cell lines (Leech & Corfe,
unpublished). Acetylation has been proposed as being as
important as phosphorylation in the regulation of protein
function [29]. This is reinforced by the observation that
HATs and HDACs are frequently mutated in cancer, which
may lead to an alteration in the acetylation landscape of
the cell permissive for cancer progression.
Taken together these data allow us to generate an hypoth-
esis that i) colorectal carcinogenesis will be associated
with an alteration in global protein acetylation, ii)
reduced levels of butyrate will cause alterations in global
protein acetylation, which may also be permissive for
colorectal cancer progression, iii) that elevation of fibre
levels and consequent butyrate levels may reduce or
reverse these processes and restore a "normal" profile of
protein acetylation.
Methodsand design
Overall Aim of the study
To determine if there is a link between global protein
acetylation, fibre intake and fermentation, and colorectal
carcinogenesis.
Primary Aims
1. To undertake a cross-sectional study of global protein
acetylation profiles in normal subjects and those with
colonic polyps and colorectal cancer. This study arm is
named FACT OBS.
2. To determine, in the same clinical groups, the relation-
ship between global protein acetylation profile and faecal
SCFA levels.
3. To undertake a fibre supplementation study in mor-
phologically normal GI patients and patients with colonic
polyps to determine the effect of fibre supplementation
on the global acetylation profile. This study arm is named
FACT INT.
Secondary Aims
1. To investigate in the above groups whether there is an
alteration in crypt proliferation index in response to car-
cinogenesis and to fibre.
2. To investigate in the above groups whether there is an
alteration in the apoptotic index in response to carcino-
genesis and to fibre.
3. To investigate in the above groups whether this is an
alteration in expression of key apoptotic regulators in
response to carcinogenesis and to fibre.
4. To establish the effect of bowel cleansing preparations
on the parameters measured under the secondary aims.
This study arm is named FACT VAL.
5. Evaluation of the EPIC Food Frequency Questionnaire
as a proxy measure of faecal SCFA.
Ethics
Ethics committee approval was obtained from the North
Sheffield Research Ethics Committee prior to recruiting
(Reference number: 06/Q2308/93)
Patient Recruitment and sample collection
FACT OBS recruitment
Recruitment targets were 30 normal, 30 polyp and 30 can-
cer patients. Patients were primarily recruited via outpa-
tient clinics and through patient databases at Sheffield's
Northern General Hospital and Royal Hallamshire Hospi-
tal. All patients were attending for diagnostic colonoscopy
and patient and researchers were unaware of the diagnosis
at time of recruitment and consent. Up to 10 biopsies
were collected at endoscopy from these patients. Biopsies
were collected with a Radial Jaw 4 2.8 mm forceps (see
table 1). Two weeks post-endoscopy, patients were asked
to provide a stool sample and completed a Food Fre-
quency Questionnaire (FFQ).
FACT VAL recruitment
Recruitment of patients to the FACT VAL arm of the study
was from the same routes as for the FACT OBS arm.
Patients indicating a willingness to return for a repeat flex-
ible sigmoidoscopy without bowel preparation were
recruited specifically to this arm of the study. The recruit-
ment target for this arm was 6 patients with a first proce-
dure following preparation with Kleanprep and 6 patients
with a first procedure following preparation with Picolax.
FACT INT recruitment
Recruitment target for the FACT INT study is 20 normal
and 20 polyp subjects consuming an habitually low fibre
diet. Patients will be recruited via the outpatients clinics
for the bowel screening programme, Northern General
Hospital, Sheffield. The biopsy protocol is summarised in
Table 1. Stool samples, FFQ and a four day food diary will
be collected circa 2 weeks after the endoscopy. Subjects
will be asked to comply with a high fibre diet for an eight
week period (including a 2 week ramp phase). Stool sam-
pling and a further food diary will be collected at the endPage 3 of 6
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second endoscopy with the same biopsying protocol.
Power calculation and sample size
There are no previous studies investigating addressing
alteration in global protein acetylation in vivo and there-
fore no data upon which to base a power calculation.
Inclusion and Exclusion Criteria
Inclusion criteria
Male subjects (FACT OBS only), Aged > 40, Low habitual
NSP and RS consumption (FACT INT only), Low level of
faecal butyrate BMI 20-29.
Exclusion criteria
Female (FACT OBS only), Cancer (FACT INT only), Habit-
ual consumers of a diet high in NSP and RS, Smokers,
Type 2 diabetics, Dieters, Inflammatory Bowel Disease.
High Fibre intervention
The primary goal of the intervention arm is to elevate
colonic SCFA levels, which will be monitored through
analysis of faecal SCFA. Elevation of fermentable fibre
intake is a rapid and amenable mechanism to achieve this
goal. Patients recruited to the FACT INT arm will be
offered a range of high-fibre foods, including switch to
wholemeal bread, fruit, dried fruit snacks, from a basket
of options identified by the research team (Additional File
1). Foods will be ordered by the researcher and delivered
by a supermarket home delivery to the patients' homes.
Compliance will be estimated and supported through
interim telephone calls and 24 hr recall estimates.
Primary outcome measure
Development of a methodology for studying global protein 
acetylation in biopsy samples and proof of principle studies
It is the goal of this study to link alterations in global pro-
teins acetylation in the colon mucosa to levels of butyrate,
the most potent HDACi produced though colonic fermen-
tation of fibre. In order to determine levels of butyrate and
other SCFA, the stool sample collected from patients will
be weighed and extracted freshly (within 3 hr of produc-
tion) using a standard procedure [29] to yield SCFA. The
absolute level of levels of each SCFA will be determined
by gas chromatography ion collaboration with Prof Chris
Seal, University of Newcastle upon Tyne. The acetylated
proteome will be analysed by a method reported else-
where (Croucher et al., in preparation), modified from a
published protocol for analysis of global protein
acetylatyion [30]. In brief, tissue samples will be lysed,
soluble protein extracted and acetyl proteins immunopre-
cipitated before separation by 2d gel electrophoresis.
Owing to the numbers of biopsies' worth of immunopre-
cipitate required for a 2d gel (6-8 biopsies), a pooling
strategy will be required for the FACT OBS analysis.
Patients will be pooled into deciles within pathology
groups (i.e. deciles within adenoma group, cancer group,
normal group) according to faecal butyrate levels, and all
biopsies in each pool will be used for a single 2d gel.
Pooling strategy for FACT INT
As larger numbers of biopsies are being taken from a sin-
gle region of the colon per patient for the FACT INT study,
no further pooling will be required.
Analysis of gels and difference discovery
The software of choice for analysis, quantitation of 2 d
gels and for identification of differences between gels will
be Samespots [31].
Residual proteome
The residual proteome (i.e. proteins not bound on the
acetyl-IP column) will be separated and analysed using an
iTRAQ workflow [32] to investigate comprehensively pos-
sible differences between the epithelial proteome in
response to carcinogenesis and to SCFA.
Secondary outcome measures
Alteration in crypt cell proliferation in i) carcinogenesis; ii) response 
to SCFA; iii) in response to elevation of SCFA
Several methodologies/measures are available for assess-
ing crypt cell proliferation rates. These include immuno-
Table 1: Position and uses of biopsies taken during endoscopy for 
the FACT OBS and FACT INT arms of this study.
Site Biopsies Purpose
FACT OBS
Mid-sigmoid 1 Whole mount
2 Immunohistochemistry
3 Proteomics
4 Proteomics
Contralateral 1 Immunohistochemistry
2 Proteomics
3 Proteomics
Lesion 1 Immunohistochemistry
2 Proteomics
3 Proteomics
FACT INT
Mid-sigmoid 1 Whole mount
2 Immunohistochemistry
3 Immunohistochemistry
4 Proteomics
5 Proteomics
6 Proteomics
7 Proteomics
8 Proteomics
9 Proteomics
10 ProteomicsPage 4 of 6
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embedded (FFPE) sections and whole mount analysis.
FFPE sections may be probed with a number of antibodies
to give a measure of cell proliferation. Antibodies to the
Ki67 antigen cross-react with all cells actively in cycle, irre-
spective of the stage in cell cycle. Some commentators sug-
gest that immunohistochemical approaches are
insufficient to measure accurately mitosis as they depend
on evaluation within a cross-section whereas mitoses will
occur in the 3d structure of the crypt [33]. Whole mount
analysis, involving the fixation of biopsies, followed by
staining with Feulgen's reagent and scoring mitosis in the
full depth of the crypt offers an alternative approach [34].
In this study we will use both Ki67 and whole mount/Fel-
ugen's as assays of crypt cell proliferation. Our prelimi-
nary findings show correlation between both indices and
suggest that Ki67 may be an adequate general index of
proliferation [35].
We will assess the relationship between fibre intake, SCFA
levels, butyrate levels, associated pathology and each of
the proliferation indices in samples collected in the FACT
OBS study. We will assess whether differences observed
attributed to either fibre/SCFA or pathology can be
reverted by elevation of fibre intake and faecal SCFA level
with samples collected in the FACT INT study.
Alteration in mucosal apoptosis in i) carcinogenesis; ii) response to 
SCFA; iii) in response to elevation of SCFA
Animal models have suggested that elevated fibre intake
and fermentation alone do not alter levels of background
apoptosis in the colon mucosa in rats. There are few if any
studies addressing directly whether apoptotic rates are
altered in response to fibre intakes/SCFA levels in
humans. Several assay methods are available for the scor-
ing of apoptosis, including antibodies to protein cleavage
products specifically generated during apotosis. The M30
antibody recognises a neoepitope produced through
cleavage of cytokeratin 18, and the CC3 antibody recog-
nises the cleaved, activated form of apoptosis-specific pro-
tease caspase 3.
As described above for the proliferation indices, we will
assess the relationship between fibre intake, SCFA levels,
butyrate levels, associated pathology and apoptositic
index in the FACT OBS study and establish wther regres-
sion to normality can be achieved through elevation of
fibre intakes through the FACT INT study.
Alteration in mucosal apoptotic regulators in i) carcinogenesis; ii) 
response to SCFA; iii) in response to elevation of SCFA
Despite elevation of SCFA not driving increased apoptosis
in the colon mucosa, there is a suggestion that the mucosa
is sensitized to damage and will show an improved apop-
totic response to cytotoxic insult. Taken together with data
from in vitro studies showing apoptosis driven by
butyrate is associated with dysregulation of Bcl2 family
proteins, we hypothesize that although no particular find-
ing may be made with the direct apoptosis assays, elevated
SCFA levels may directly and measurably alter Bcl2 family
expression.
Of particular interest are the pro-apoptotic members of
the family, Bax and BAK. We will determine levels of
expression using semi-quantitative immunohistochemi-
cal approaches. Bax, BAK and the anti-apoptotic protein
Bcl2 will be determined in the FACT OBS and FACT INT
studies.
Discussion
The study aims to investigate for the first time the effects
of fibre intake and disease pathology on global protein
acetylation, and to link this data to commonly used meas-
ures of cell fate (cell division and cell death) whose
derangement is a hallmark of cancer [36]. The approaches
developed may yield novel biomarkers of either or both of
fibre consumption or SCFA production and of the earliest
stages of carcinogenesis. By establishing the potential for
such biomarkers to revert to normality and linking these
reversions to cellular events on the proliferative and apop-
totic pathways we may in the medium term develop
improved approaches to the promotion of colon health.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
BMC Conceived the project, directs the overall project,
directed the proteomics method development and wrote
the manuscript; EAW contributed to the study design,
directs recruiting and nutritional analysis; JPB contributed
to study design, directs immunohistochemical methods
and analysis; SAR is the clinical lead for the study, contrib-
uted to the study design, undertakes endoscopy and
directs clinical procedures; LJC developed methods for
separation of acetyl proteins and undertakes immunohis-
tochemical analysis; DYLL undertakes patient recruiting,
intervention strategy and nutritional analysis; CAE con-
ceived and undertakes quantitative proteomic analysis.
All authors read and approved the final manuscript.
Additional material
Additional file 1
Food choice form developed for high fibre foods offered as supplements in 
the FACT INT arms of this study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-9-332-S1.DOC]Page 5 of 6
(page number not for citation purposes)
BMC Cancer 2009, 9:332 http://www.biomedcentral.com/1471-2407/9/332Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Acknowledgements
This study was reviewed and funded by the Food Standards Agency (ref: 
N12017).
References
1. Burkitt DP: Related disease - related cause?  Lancet 1969,
2(7632):1229-1231.
2. World Cancer Research Fund/American Institute for Cancer
Research: Food, nutrition, physical activity and the prevention
of cancer: a global perspective.  Washington DC: AICR; 2007. 
3. Bonithon-Kopp C, Kronborg O, Giacosa A, Räth U, Faivre J: Cal-
cium and fibre supplementation in prevention of colorectal
adenoma recurrence: a randomised intervention trial. Euro-
pean Cancer Prevention Organisation Study Group.  Lancet
2000, 356:1300-6.
4. Schatzkin A, Lanza E, Corle D, Lance P, Iber F, Caan B, Shike M,
Weissfeld J, Burt R, Cooper MR, Kikendall JW, Cahill J: Lack of
effect of a low-fat, high-fiber diet on the recurrence of color-
ectal adenomas. Polyp Prevention Trial Study Group.  N Engl
J Med 2000, 342:1149-55.
5. Hill MJ: Vegetables, fruits, fibre and colorectal cancer.  Eur J
Cancer Prev 2002, 11:1-2.
6. Arasaradnam RP, Riley SA, Corfe BM: Dietary fibre - back on the
menu?  Gut 2004, 53:155-156.
7. McIntyre A, Gibson PR, Young GP: Butyrate production from
dietary fibre and protection against large bowel cancer in a
rat model.  Gut 1993, 34:386-91.
8. Roediger WE: Utilization of nutrients by isolated epithelial
cells of the rat colon.  Gastroenterology 1982, 83:424-9.
9. Toscani A, Soprano DR, Soprano KJ: Molecular analysis of sodium
butyrate-induced growth arrest.  Oncogene Res 1988, 3:223-38.
10. Hofmanová J, Vaculová A, Koubková Z, Hýžd'alová M, Kozubík A:
Human fetal colon cells and colon cancer cells respond dif-
ferently to butyrate and PUFAs.  Mol Nutr Food Res 2009,
53:S102-113.
11. Prais AL, Dive C, Corfe BM: Butyrate-mediated cell cycle arrest
of HCT116 colon carcinoma cells is accompanied by hyper-
ploidy.  In Proceedings of Hydrocolloids as Gums and Stabilisers in the
Food Industry 12 Edited by: Williams PA, Phillips GO. Royal Society of
Chemistry, Cambridge; 2004. 
12. Ruemmele FM, Dionne S, Qureshi I, Sarma DS, Levy E, Seidman EG:
Butyrate mediates Caco-2 cell apoptosis via up-regulation of
pro-apoptotic BAK and inducing caspase-3 mediated cleav-
age of poly-(ADP-ribose) polymerase (PARP).  Cell Death Differ
1999, 6:729-35.
13. Ruemmele FM, Schwartz S, Seidman EG, Dionne S, Levy E, Lentze MJ:
Butyrate induced Caco-2 cell apoptosis is mediated via the
mitochondrial pathway.  Gut 2003, 52:94-100.
14. Chirakkal H, Leech SH, Brookes KE, Prais AL, Waby JS, Corfe BM:
Upregulation of BAK by butyrate in the colon is associated
with increased Sp3 binding.  Oncogene 2006, 25:7192-200.
15. Inagaki A, Sakata T: Dose-dependent stimulatory and inhibitory
effects of luminal and serosal n-butyric acid on epithelial cell
proliferation of pig distal colonic mucosa.  J Nutr Sci Vitaminol
(Tokyo) 2005, 51:156-60.
16. Sakata T, von Engelhardt W: Stimulatory effect of short chain
fatty acids on the epithelial cell proliferation in rat large
intestine.  Comp Biochem Physiol A Comp Physiol 1983, 74:459-62.
17. Sakata T, Kojima T, Fujeida M, Takahashi M, Michibata T: Influences
of probiotic bacteria on organic acids production by pig cae-
cal bacteria in vitro.  Proc Nutr Soc 2003, 62:73-80.
18. Hass R, Busche R, Luciano L, Reale E, Engelhardt WV: Lack of
butyrate is associated with induction of Bax and subsequent
apoptosis in the proximal colon of guinea pig.  Gastroenterology
1997, 112:875-81.
19. Cole JW, Holden WD: Postcolectomy regression of adenoma-
tous polyps of the rectum.  Arch Surg 1959, 79:385-92.
20. Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bartram P,
Christl S, Richter F, Dusel G, Kasper H: Effect of butyrate enemas
on the colonic mucosa in distal ulcerative colitis.  Gastroenter-
ology 1992, 103:51-6.
21. Le Leu RK, Hu Y, Young GP: Effects of resistant starch and non-
starch polysaccharides on colonic luminal environment and
genotoxin-induced apoptosis in the rat.  Carcinogenesis 2002,
23:713-9.
22. Le Leu RK, Brown IL, Hu Y, Young GP: Effect of resistant starch
on genotoxin-induced apoptosis, colonic epithelium, and
lumenal contents in rats.  Carcinogenesis 2003, 24:1347-52.
23. Sealy L, Chalkley R: The effect of sodium butyrate on histone
modification.  Cell 1978, 14:115-21.
24. Seigneurin-Berny D, Verdel A, Curtet S, Lemercier C, Garin J, Rousseaux
S, Khochbin S: Identification of components of the murine his-
tone deacetylase 6 complex: link between acetylation and ubiq-
uitination signaling pathways.  Mol Cell Biol 2001, 21:8035-44.
25. Sun JM, Spencer VA, Chen HY, Li L, Davie JR: Measurement of his-
tone acetyltransferase and histone deacetylase activities and
kinetics of histone acetylation.  Methods 2003, 31:12-23.
26. Dwarakanath BS, Verma A, Bhatt AN, Parmar VS, Raj HG: Targeting
protein acetylation for improving cancer therapy.  Indian J Med
Res 2008, 128:13-21.
27. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E: The human
Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin
deacetylase.  Mol Cell 2003, 11:437-44.
28. Leech SH, Evans CA, Shaw L, Wong CH, Connolly J, Griffiths JR, Whet-
ton AD, Corfe BM: Proteomic analyses of intermediate fila-
ments reveals cytokeratin8 is highly acetylated--implications
for colorectal epithelial homeostasis.  Proteomics 2008, 8:279-88.
29. Seal CJ, Mathers JC: Comparative gastrointestinal and plasma
cholesterol responses of rats fed on cholesterol-free diets
supplemented with guar gum and sodium alginate.  Br J Nutr
2001, 85:317-24.
30. Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J, Cheng T, Kho Y, Xiao
H, Xiao L, Grishin NV, White M, Yang XJ, Zhao Y: Substrate and
Functional Diversity of Lysine Acetylation Revealed by a
Proteomics Survey.  Mol Cell 2006, 23:607-618.
31. Karp NA, Feret R, Rubtsov DV, Lilley KS: Comparison of DIGE
and post-stained gel electrophoresis with both traditional
and SameSpots analysis for quantitative proteomics.  Pro-
teomics 2008, 8:948-60.
32. Glen A, Gan CS, Hamdy FC, Eaton CL, Cross SS, Catto JW, Wright
PC, Rehman I: iTRAQ-facilitated proteomic analysis of human
prostate cancer cells identifies proteins associated with pro-
gression.  J Proteome Res 2008, 7:897-907.
33. Alferez D, Goodlad RA: To best measure cell proliferation in
samples from the intestine.  Cell Prolif 2007, 40:231-40.
34. Goodlad RA, Levi S, Lee CY, Mandir N, Hodgson H, Wright NA:
Morphometry and cell proliferation in endoscopic biopsies:
evaluation of a technique.  Gastroenterology 1991, 101:1235-41.
35. Croucher L, Norwood H, Riley S, Williams E, Corfe B, Bury J:
Assessing proliferation in colorectal biopsies: a comparison
of Ki-67 immunohistochemistry with counting mitoses in
whole crypts.  J Pathol 2007, 213:9A.
36. Hanahan D, Weinberg RA: The hallmarks of cancer.  Cell 2000,
100:57-70.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/332/pre
pubPage 6 of 6
(page number not for citation purposes)
